These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 35468223)

  • 1. Suppression of MYC by PI3K/AKT/mTOR pathway inhibition in combination with all-trans retinoic acid treatment for therapeutic gain in acute myeloid leukaemia.
    Stengel S; Petrie KR; Sbirkov Y; Stanko C; Ghazvini Zadegan F; Gil V; Skopek R; Kamiński P; Szymański Ł; Brioli A; Zelent A; Schenk T
    Br J Haematol; 2022 Jul; 198(2):338-348. PubMed ID: 35468223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined inhibition of PI3K and mTOR exerts synergistic antiproliferative effect, but diminishes differentiative properties of rapamycin in acute myeloid leukemia cells.
    Mise J; Dembitz V; Banfic H; Visnjic D
    Pathol Oncol Res; 2011 Sep; 17(3):645-56. PubMed ID: 21336564
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salt-inducible kinase inhibition sensitizes human acute myeloid leukemia cells to all-trans retinoic acid-induced differentiation.
    Zhang XW; Shen X; Long WY; Xiao H; Li FJ; Xing S; Xiong GL; Yu ZY; Cong YW
    Int J Hematol; 2021 Feb; 113(2):254-262. PubMed ID: 33074481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells.
    Ozpolat B; Akar U; Steiner M; Zorrilla-Calancha I; Tirado-Gomez M; Colburn N; Danilenko M; Kornblau S; Berestein GL
    Mol Cancer Res; 2007 Jan; 5(1):95-108. PubMed ID: 17259349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Complexity of Targeting PI3K-Akt-mTOR Signalling in Human Acute Myeloid Leukaemia: The Importance of Leukemic Cell Heterogeneity, Neighbouring Mesenchymal Stem Cells and Immunocompetent Cells.
    Brenner AK; Andersson Tvedt TH; Bruserud Ø
    Molecules; 2016 Nov; 21(11):. PubMed ID: 27845732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin module for acute myelogenous leukemia therapy: from bench to bedside.
    Martelli AM; Tazzari PL; Evangelisti C; Chiarini F; Blalock WL; Billi AM; Manzoli L; McCubrey JA; Cocco L
    Curr Med Chem; 2007; 14(19):2009-23. PubMed ID: 17691943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting PI3K/AKT/mTOR pathway to enhance the anti-leukemia efficacy of venetoclax.
    Liu H; Hussain Z; Xie Q; Yan X; Zeng C; Zhou G; Cao S
    Exp Cell Res; 2022 Aug; 417(2):113192. PubMed ID: 35568072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of mammalian target of rapamycin signaling potentiates the effects of all-trans retinoic acid to induce growth arrest and differentiation of human acute myelogenous leukemia cells.
    Nishioka C; Ikezoe T; Yang J; Gery S; Koeffler HP; Yokoyama A
    Int J Cancer; 2009 Oct; 125(7):1710-20. PubMed ID: 19507250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual inhibition of PI3K and mTORC1/2 signaling by NVP-BEZ235 as a new therapeutic strategy for acute myeloid leukemia.
    Chapuis N; Tamburini J; Green AS; Vignon C; Bardet V; Neyret A; Pannetier M; Willems L; Park S; Macone A; Maira SM; Ifrah N; Dreyfus F; Herault O; Lacombe C; Mayeux P; Bouscary D
    Clin Cancer Res; 2010 Nov; 16(22):5424-35. PubMed ID: 20884625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The phosphatidylinositol 3-kinase/Akt/mTOR signaling network as a therapeutic target in acute myelogenous leukemia patients.
    Martelli AM; Evangelisti C; Chiarini F; McCubrey JA
    Oncotarget; 2010 Jun; 1(2):89-103. PubMed ID: 20671809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual PI3K/mTOR inhibition shows antileukemic activity in MLL-rearranged acute myeloid leukemia.
    Sandhöfer N; Metzeler KH; Rothenberg M; Herold T; Tiedt S; Groiß V; Carlet M; Walter G; Hinrichsen T; Wachter O; Grunert M; Schneider S; Subklewe M; Dufour A; Fröhling S; Klein HG; Hiddemann W; Jeremias I; Spiekermann K
    Leukemia; 2015 Apr; 29(4):828-38. PubMed ID: 25322685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of CCAAT enhancer binding protein α P42 induces myeloid differentiation and overcomes all-trans retinoic acid resistance in human acute promyelocytic leukemia NB4-R1 cells.
    Wang L; Xiao H; Zhang X; Liao W; Fu S; Huang H
    Int J Oncol; 2015 Nov; 47(5):1685-95. PubMed ID: 26397153
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells.
    Nepstad I; Hatfield KJ; Grønningsæter IS; Reikvam H
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32326335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resistance to the Antiproliferative In Vitro Effect of PI3K-Akt-mTOR Inhibition in Primary Human Acute Myeloid Leukemia Cells Is Associated with Altered Cell Metabolism.
    Nepstad I; Reikvam H; Brenner AK; Bruserud Ø; Hatfield KJ
    Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29382066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect.
    Reikvam H; Tamburini J; Skrede S; Holdhus R; Poulain L; Ersvaer E; Hatfield KJ; Bruserud Ø
    Br J Haematol; 2014 Jan; 164(2):200-11. PubMed ID: 24383842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in acute myeloid leukemia revealed by pathway selective inhibition and phosphoproteome analysis.
    Bertacchini J; Guida M; Accordi B; Mediani L; Martelli AM; Barozzi P; Petricoin E; Liotta L; Milani G; Giordan M; Luppi M; Forghieri F; De Pol A; Cocco L; Basso G; Marmiroli S
    Leukemia; 2014 Nov; 28(11):2197-205. PubMed ID: 24699302
    [TBL] [Abstract][Full Text] [Related]  

  • 18. All-trans retinoic acid modulates Wnt3A-induced osteogenic differentiation of mesenchymal stem cells via activating the PI3K/AKT/GSK3β signalling pathway.
    Zhang S; Chen X; Hu Y; Wu J; Cao Q; Chen S; Gao Y
    Mol Cell Endocrinol; 2016 Feb; 422():243-253. PubMed ID: 26747727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
    Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
    Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways.
    Tamburini J; Chapuis N; Bardet V; Park S; Sujobert P; Willems L; Ifrah N; Dreyfus F; Mayeux P; Lacombe C; Bouscary D
    Blood; 2008 Jan; 111(1):379-82. PubMed ID: 17878402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.